A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (RALLY)
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia
Sponsor: Tonix Pharmaceuticals, Inc.
Listed as NCT04508621, this PHASE3 trial focuses on Fibromyalgia and remains completed. Sponsored by Tonix Pharmaceuticals, Inc., it has been updated 12 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Terminated → Completed
-
Jan 2023 — Jan 2024 [monthly]
Terminated PHASE3
-
Jan 2022 — Jan 2023 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
▶ Show 7 earlier versions
-
Sep 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Jul 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tonix Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .